» Articles » PMID: 36287107

HDAC1 Regulates the Chromatin Landscape to Control Transcriptional Dependencies in Chronic Lymphocytic Leukemia

Abstract

Chronic lymphocytic leukemia (CLL) is a quiescent B-cell malignancy that depends on transcriptional dysregulation for survival. The histone deacetylases are transcriptional regulators whose role within the regulatory chromatin and consequence on the CLL transcriptome is poorly characterized. Here, we profiled and integrated the genome-wide occupancy of HDAC1, BRD4, H3K27Ac, and H3K9Ac signals with chromatin accessibility, Pol2 occupancy, and target expression signatures in CLL cells. We identified that when HDAC1 was recruited within super-enhancers (SEs) marked by acetylated H3K27 and BRD4, it functioned as a transcriptional activator that drove the de novo expression of select genes to facilitate survival and progression in CLL. Targeting HDACs reduced BRD4 and Pol2 engagement to downregulate the transcript and proteins levels of specific oncogenic driver genes in CLL such as BLK, a key mediator of the B-cell receptor pathway, core transcription factors such as PAX5 and IKZF3, and the antiapoptotic gene, BCL2. Concurrently, HDAC1, when recruited in the absence of SEs, repressed target gene expression. HDAC inhibition reversed silencing of a defined set of protein-coding and noncoding RNA genes. We focused on a specific set of microRNA genes and showed that their upregulation was inversely correlated with the expression of CLL-specific survival, transcription factor, and signaling genes. Our findings identify that the transcriptional activator and repressor functions of HDACs cooperate within the same tumor to establish the transcriptional dependencies essential for survival in CLL.

Citing Articles

HDAC-driven mechanisms in anticancer resistance: epigenetics and beyond.

Minisini M, Mascaro M, Brancolini C Cancer Drug Resist. 2024; 7:46.

PMID: 39624079 PMC: 11609180. DOI: 10.20517/cdr.2024.103.


MicroRNA-Mediated Regulation of Histone-Modifying Enzymes in Cancer: Mechanisms and Therapeutic Implications.

Szczepanek J, Tretyn A Biomolecules. 2023; 13(11).

PMID: 38002272 PMC: 10669115. DOI: 10.3390/biom13111590.


Nucleosome repositioning in chronic lymphocytic leukemia.

Piroeva K, McDonald C, Xanthopoulos C, Fox C, Clarkson C, Mallm J Genome Res. 2023; 33(10):1649-1661.

PMID: 37699659 PMC: 10691546. DOI: 10.1101/gr.277298.122.


Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies.

Markouli M, Strepkos D, Piperi C Int J Mol Sci. 2022; 23(21).

PMID: 36362442 PMC: 9654260. DOI: 10.3390/ijms232113657.

References
1.
Greer C, Tanaka Y, Kim Y, Xie P, Zhang M, Park I . Histone Deacetylases Positively Regulate Transcription through the Elongation Machinery. Cell Rep. 2015; 13(7):1444-1455. PMC: 4934896. DOI: 10.1016/j.celrep.2015.10.013. View

2.
Roberts A, Davids M, Pagel J, Kahl B, Puvvada S, Gerecitano J . Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 374(4):311-22. PMC: 7107002. DOI: 10.1056/NEJMoa1513257. View

3.
Buchner M, Muschen M . Targeting the B-cell receptor signaling pathway in B lymphoid malignancies. Curr Opin Hematol. 2014; 21(4):341-9. PMC: 4136419. DOI: 10.1097/MOH.0000000000000048. View

4.
Bottoni A, Rizzotto L, Lai T, Liu C, Smith L, Mantel R . Targeting BTK through microRNA in chronic lymphocytic leukemia. Blood. 2016; 128(26):3101-3112. PMC: 5201097. DOI: 10.1182/blood-2016-07-727750. View

5.
Ozer H, El-Gamal D, Powell B, Hing Z, Blachly J, Harrington B . BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor. Cancer Discov. 2018; 8(4):458-477. PMC: 5882533. DOI: 10.1158/2159-8290.CD-17-0902. View